100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Definitive Contract HHSO100201500003C
Award Date
12/23/14
Potential Completion Date
6/30/17
Potential Value
$6.4M
Overview
Contacts
Activity
4
Transactions
4
Subawards
Opportunity Stack
Similar Awards
Federal Agency
Office of the Assistant Secretary for Preparedness and Response
Awardee
Glaxosmithkline, LLC FRHTPHMZMX47
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
AN13 - Health R&D Services; Health Care Services; Experimental Development
Federal Contract Vehicle
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Durham, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
20
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Update #1
Update #2
GSK EBOLA
Posted 12/23/14
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
Medical Research
Added: Jul 16, 2013 11:39 am BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the teat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2012 PHEMCE Implementation Plan for CBRN Teats. The Implementation Plan is located on the ASPR website: https://www.medicalcountermeasures.gov/media/13962/2012-phemce-implementation-plan.pdf The Pandemic and All Hazard Preparedness Act Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA; http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act Pub. L. No. 113-5, (PAHPRA: http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) authorizes BARDA to (i) conduct ongoing searches for, and support calls for, potential qualified countermeasures and qualified pandemic or epidemic products; (ii) direct and coordinate the countermeasure and product advanced research and development activities of the Department of Health and Human Services; (iii) establish strategic initiatives to accelerate countermeasure and product advanced research and development (which may include advanced research and development for purposes of fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or section 351 of this Act) and innovation in such areas as the Secretary may identify as priority unmet need areas; and (iv) award contracts, grants, cooperative agreements, and enter into other transactions, for countermeasure and product advanced research and development. Areas of Interest:The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.Research Areas of Interest:1. Vaccines 2. Antitoxins and Therapeutics3. Antimicrobial Drugs4. Radiological/Nuclear Teat Medical Countermeasures5. Chemical Teat Medical Countermeasures6. Clinical Diagnostics ToolsBARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN teats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA itself is anticipated to be posted on or about July 31, 2013. The Government expects to make 1 or more awards, subject to the availability of funds. The open period of the BAA will be specified in the BAA itself.Contact Information:Comments to this announcement, referencing synopsis BAA- 13-100-SOL-00013 may be submitted to the following email address: CBRN-BAA-13@hhs.govContracting Office Address:Department of Health & Human Services (DHHS)Office of the Assistant Secretary for Preparedness & Response (ASPR) Acquisition Management Contracts & Grants (AMCG)330 Independence Ave., S.W., Room G-640Washington, D.C. 20201
BAA-13-100-SOL-00013
Department of Health and Human Services Immediate Office of the Secretary
Award Notice 1/1
7/16/13, 11:39 AM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
P00003
MODIFICATION 3: CONCLUDE FINAL CLOSE-OUT ACTIVITIES THROUGH DEOBLIGATION OF $1,111,656.93
Close Out
($1m)
12/31/16
2
GSK EBOLA
Funding Only Action
($6m)
12/16/16
1
GSK EBOLA
Change Order
$0
9/28/16
Not listed
GSK EBOLA
Not listed
$13.0m
12/23/14